Cargando…

Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation

Premature ejaculation (PE) is a major issue in male sexual health. The global prevalence of PE is estimated to be between 20% and 40%, making it the most common sexual dysfunction in men. PE causes distress and reduced quality of life for patients and has a negative impact on interpersonal relations...

Descripción completa

Detalles Bibliográficos
Autores principales: McCarty, EJ, Dinsmore, WW
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273363/
https://www.ncbi.nlm.nih.gov/pubmed/22315582
http://dx.doi.org/10.2147/CE.S13841
_version_ 1782222926259421184
author McCarty, EJ
Dinsmore, WW
author_facet McCarty, EJ
Dinsmore, WW
author_sort McCarty, EJ
collection PubMed
description Premature ejaculation (PE) is a major issue in male sexual health. The global prevalence of PE is estimated to be between 20% and 40%, making it the most common sexual dysfunction in men. PE causes distress and reduced quality of life for patients and has a negative impact on interpersonal relationships. Historically, it has been treated with cognitive therapy, behavioral methods, and off-label use of selective serotonin reuptake inhibitors usually used to treat depression and other psychological disorders. Dapoxetine is a selective serotonin reuptake inhibitor specifically designed to treat PE. This paper reviews the current evidence for use of dapoxetine in the treatment of PE in adult men. There is substantial evidence that dapoxetine 30 mg or 60 mg taken “on-demand” results in a significant increase in intravaginal ejaculatory latency time when compared with placebo. Patient-reported outcomes are clearly improved relative to placebo following dapoxetine therapy, indicating greater control over ejaculation, more satisfaction with intercourse, less ejaculation-related distress, and, importantly, significantly reduced interpersonal difficulty. These data were supported by consistent reports of improvement in Clinical Global Impression of change in PE following treatment with dapoxetine. Further studies are needed to evaluate long-term efficacy and health economics. The unique pharmacology of dapoxetine makes it ideal for on-demand dosing, and the clinical evidence shows dapoxetine to be an efficacious and tolerable treatment for lifelong and acquired PE.
format Online
Article
Text
id pubmed-3273363
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-32733632012-02-07 Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation McCarty, EJ Dinsmore, WW Core Evid Review Premature ejaculation (PE) is a major issue in male sexual health. The global prevalence of PE is estimated to be between 20% and 40%, making it the most common sexual dysfunction in men. PE causes distress and reduced quality of life for patients and has a negative impact on interpersonal relationships. Historically, it has been treated with cognitive therapy, behavioral methods, and off-label use of selective serotonin reuptake inhibitors usually used to treat depression and other psychological disorders. Dapoxetine is a selective serotonin reuptake inhibitor specifically designed to treat PE. This paper reviews the current evidence for use of dapoxetine in the treatment of PE in adult men. There is substantial evidence that dapoxetine 30 mg or 60 mg taken “on-demand” results in a significant increase in intravaginal ejaculatory latency time when compared with placebo. Patient-reported outcomes are clearly improved relative to placebo following dapoxetine therapy, indicating greater control over ejaculation, more satisfaction with intercourse, less ejaculation-related distress, and, importantly, significantly reduced interpersonal difficulty. These data were supported by consistent reports of improvement in Clinical Global Impression of change in PE following treatment with dapoxetine. Further studies are needed to evaluate long-term efficacy and health economics. The unique pharmacology of dapoxetine makes it ideal for on-demand dosing, and the clinical evidence shows dapoxetine to be an efficacious and tolerable treatment for lifelong and acquired PE. Dove Medical Press 2012 2012-01-19 /pmc/articles/PMC3273363/ /pubmed/22315582 http://dx.doi.org/10.2147/CE.S13841 Text en © 2012 McCarty and Dinsmore, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
McCarty, EJ
Dinsmore, WW
Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation
title Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation
title_full Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation
title_fullStr Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation
title_full_unstemmed Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation
title_short Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation
title_sort dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273363/
https://www.ncbi.nlm.nih.gov/pubmed/22315582
http://dx.doi.org/10.2147/CE.S13841
work_keys_str_mv AT mccartyej dapoxetineanevidencebasedreviewofitseffectivenessintreatmentofprematureejaculation
AT dinsmoreww dapoxetineanevidencebasedreviewofitseffectivenessintreatmentofprematureejaculation